

| Numéro de catalogue | HV145021 |
|---|---|
| Description |
Recombinant Human CD367/CLEC4A Protein, C-Fc (HV145021) expressed in Mammalian Cells, spanning Gln70-Leu237. Purity: >90% by SDS-PAGE.
Highlights
|
| Système d'expression | Mammalian cells |
| Numéro d'accès | Q9UMR7 |
| Longueur de protéine | Gln70-Leu237 |
| Applications | ELISA, Immunogen, SDS-PAGE, WB, Bioactivity testing in progress |
| Espèces | Homo sapiens (Human) |
| Nature | Recombinant |
| Niveau d'endotoxines | Please contact with the lab for this information. |
| Pureté | >90% as determined by SDS-PAGE. |
| Masse moléculaire prédite | 48.19 kDa |
| Forme | Lyophilized |
| Tampon de stockage | Lyophilized from a solution in PBS pH 7.4, 1 mM EDTA, 4% Trehalose, 1% Mannitol. Reférez-vous aux informations spécifiques sur le tampon dans la copie papier du datasheet ou dans le COA spécifique au lot. |
| Reconstitution | Reconstitute in sterile water for a stock solution. A copy of datasheet will be provided with the products, please refer to it for details. |
| Expédition | In general, proteins are provided as lyophilized powder/frozen liquid. They are shipped out with dry ice/blue ice unless customers require otherwise. |
| Stabilité et stockage | Use a manual defrost freezer and avoid repeated freeze thaw cycles. Store at 2 to 8°C for frequent use. Store at -20 to -80°C for twelve months from the date of receipt. |
| Noms alternatifs | C-type lectin DDB27, C-type lectin domain family 4 member A, C-type lectin superfamily member 6, CD367, CLEC4A, CLECSF6, DCIR, Dendritic cell immunoreceptor, LLIR, Lectin-like immunoreceptor |
| Contexte | C-type lectin domain family 4 member A is a ~27 kDa protein. C-type lectin receptor that binds carbohydrates mannose and fucose but also weakly interacts with N-acetylglucosamine (GlcNAc) in a Ca(2+)-dependent manner. Involved in regulating immune reactivity. Once triggered by antigen, it is internalized by clathrin-dependent endocytosis and delivers its antigenic cargo into the antigen presentation pathway resulting in cross-priming of CD8(+) T cells. This cross-presentation and cross-priming are enhanced by TLR7 and TLR8 agonists with increased expansion of the CD8(+) T cells, high production of IFNG and TNF with reduced levels of IL4, IL5 and IL13. In plasmacytoid dendritic cells, inhibits TLR9-mediated IFNA and TNF production. 1. Nagae, M. et al. (2016) FEBS letters 590, 1280-8. PMID: 27015765 2. Bates, EE. et al. (1999) Journal of immunology (Baltimore, Md. : 1950) 163, 1973-83. PMID: 10438934 3. Meyer-Wentrup, F. et al. (2008) Blood 111, 4245-53. PMID: 18258799 4. Klechevsky, E. et al. (2010) Blood 116, 1685-97. PMID: 20530286 |
| Note | For research use only |




Contactez-nous pour les devis personnalisés, les demandes en gros et tout autre problème.
Courrier : [email protected]
+86-027-65523339
Bâtiment C, No. 666, Rue Shendunsi, Wuhan, 430206, Chine
中文
English
한국어
日本語
Español
Français
Русский